- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Undervalued Small Caps With Insider Buying
Global Pharmaceuticals & Biotech Undervalued Small Caps With Insider Buying
Results
3
Smaller, under-the-radar companies, backed by insider buying, presenting a compelling opportunity for investors seeking undervalued gems.
3 companies
Oxford Biomedica
Market Cap: UK£669.4m
A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
OXB
UK£5.57
7D
11.0%
1Y
61.7%
Azenta
Market Cap: US$1.4b
Provides biological and chemical compound sample exploration and management solutions for the life sciences market in the United States, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally.
AZTA
US$30.20
7D
1.4%
1Y
-37.9%
DiaMedica Therapeutics
Market Cap: US$312.5m
A clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases.
DMAC
US$5.98
7D
-0.3%
1Y
49.9%